Streck gets IVD clearance for controls, launches blood collection tube

August 2026—Streck has received in vitro diagnostic clearance for three MDx-Chex controls for sepsis testing. MDx-Chex for BCY, MDx-Chex for BCP, and MDx-Chex for BCN are patient-like, ready-to-use, full-process molecular quality controls designed for verification of the Diasorin Liaison Plex yeast, Gram-positive, and Gram-negative blood culture assays, respectively. The controls are supplied in 10 single-use vial kits and feature room-temperature storage.

In a separate release, Streck announced the launch of its Nucleic Acid Plus BCT blood collection tube. The new tube, formerly known as Protein Plus BCT, has expanded intended use claims to include cell-free DNA, cell-free RNA, extracellular vesicles, and select plasma proteins. It provides stabilization of whole blood samples at ambient temperature (18°–25°C), with cf­DNA and cfRNA remaining stable in stored samples for up to seven days and extracellular vesicles and select plasma proteins remaining stable up to five days, allowing for multianalyte analysis from a single draw. The proprietary preservative reagent stabilizes nucleated blood cells, red blood cells, and platelets while minimizing ex vivo hemolysis and platelet activation.

Nucleic Acid Plus BCT is for research use only and available as a 5-mL configuration in packs of six, boxes of 100, or cases of 1,000. A 10-mL configuration is expected to launch later this year.

Streck, 800-843-0912